Surmodics Inc
NASDAQ:SRDX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
25.39
42.24
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SRDX stock under the Base Case scenario is 15.29 USD. Compared to the current market price of 39.33 USD, Surmodics Inc is Overvalued by 61%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Surmodics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for SRDX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Surmodics Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Surmodics Inc
Balance Sheet Decomposition
Surmodics Inc
Current Assets | 81.3m |
Cash & Short-Term Investments | 40.1m |
Receivables | 23.2m |
Other Current Assets | 18m |
Non-Current Assets | 97.3m |
PP&E | 25m |
Intangibles | 68.2m |
Other Non-Current Assets | 4.1m |
Current Liabilities | 20.5m |
Other Current Liabilities | 20.5m |
Non-Current Liabilities | 39.1m |
Long-Term Debt | 29.6m |
Other Non-Current Liabilities | 9.6m |
Earnings Waterfall
Surmodics Inc
Revenue
|
126.1m
USD
|
Cost of Revenue
|
-33m
USD
|
Gross Profit
|
93.1m
USD
|
Operating Expenses
|
-98.7m
USD
|
Operating Income
|
-5.6m
USD
|
Other Expenses
|
-5.9m
USD
|
Net Income
|
-11.5m
USD
|
Free Cash Flow Analysis
Surmodics Inc
USD | |
Free Cash Flow | USD |
Surmodics reported robust revenue growth of 18% year-over-year at $32 million, mainly driven by a 40% increase in medical device product sales. Key products like SurVeil DCB and Pounce thrombectomy significantly contributed. The company improved its fiscal 2024 guidance to $122–$124 million, expecting operational revenue growth of 15% to 17%. GAAP net income turned positive to $250,000 from a $7.7 million loss last year. They also ended the quarter with $40.9 million in cash. Surmodics aims for sustained growth and continued investments in their vascular interventions portfolio.
What is Earnings Call?
SRDX Profitability Score
Profitability Due Diligence
Surmodics Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
Surmodics Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
SRDX Solvency Score
Solvency Due Diligence
Surmodics Inc's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Score
Surmodics Inc's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SRDX Price Targets Summary
Surmodics Inc
According to Wall Street analysts, the average 1-year price target for SRDX is 43.86 USD with a low forecast of 43.43 USD and a high forecast of 45.15 USD.
Dividends
Current shareholder yield for SRDX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
SRDX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The firm operates through two segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.
Contact
IPO
Employees
Officers
The intrinsic value of one SRDX stock under the Base Case scenario is 15.29 USD.
Compared to the current market price of 39.33 USD, Surmodics Inc is Overvalued by 61%.